Centre of Defence Pathology, Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK; Clinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Clinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Diagn Microbiol Infect Dis. 2022 Nov;104(3):115788. doi: 10.1016/j.diagmicrobio.2022.115788. Epub 2022 Aug 12.
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.
单克隆抗体疗法已获准用于预防和治疗严重的 COVID-19 感染。最大的益处似乎仅限于那些尚未从自然感染或接种疫苗中产生有效免疫反应的人，但人们担心在以基于实验室的血清学诊断为主的情况下，能否及时评估基于社区的患者的免疫状态。邀请参与者进行配对的基于实验室的（雅培 Architect SARS-CoV-2 IgG Quant II 化学发光微粒子免疫分析）和侧向流动检测（LFA；一种拆分的 SARS-CoV-2 IgM/IgG 和总抗体检测），以检测 SARS-CoV-2 抗刺突抗体。通过对数线性回归比较 LFA 带强度与 CMIA 滴度。200 名个体（中位年龄 43.5 岁，IQR 30-59；60.5%为女性）接受了检测，另有 100 份对照血清进行了检测。LFA 带强度与 CMIA 抗体滴度均呈强相关性（P<0.001）。LFA 有可能帮助早期识别血清阴性患者，这些患者可能从单克隆抗体治疗中获益最大。
